-
1
-
-
33845882230
-
-
Dzau VJ, Antman EM, Black HR, et al. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part II: Clinical trial evidence (acute coronary syndromes through renal disease) and future directions. Circulation. 2006;114(25):2871-2891.
-
Dzau VJ, Antman EM, Black HR, et al. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part II: Clinical trial evidence (acute coronary syndromes through renal disease) and future directions. Circulation. 2006;114(25):2871-2891.
-
-
-
-
2
-
-
33845902544
-
-
Dzau VJ, Antman EM, Black HR, et al. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation. 2006;114(25):2850-2870.
-
Dzau VJ, Antman EM, Black HR, et al. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation. 2006;114(25):2850-2870.
-
-
-
-
3
-
-
0027423351
-
The epidemiology of heart failure: The Framingham Study
-
Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol. 1993;22(4 Suppl A):6A-13A.
-
(1993)
J Am Coll Cardiol
, vol.22
, Issue.4 SUPPL. A
-
-
Ho, K.K.1
Pinsky, J.L.2
Kannel, W.B.3
Levy, D.4
-
4
-
-
0035922695
-
Cardiovascular protection and blood pressure reduction: A meta-analysis
-
Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet. 2001;358(9290):1305-1315.
-
(2001)
Lancet
, vol.358
, Issue.9290
, pp. 1305-1315
-
-
Staessen, J.A.1
Wang, J.G.2
Thijs, L.3
-
5
-
-
18844366399
-
Mechanisms for the clinical benefits of angiotensin II receptor blockers
-
Schmieder RE. Mechanisms for the clinical benefits of angiotensin II receptor blockers. Am J Hypertens. 2005;18(5 Pt 1):720-730.
-
(2005)
Am J Hypertens
, vol.18
, Issue.5 PART 1
, pp. 720-730
-
-
Schmieder, R.E.1
-
6
-
-
0037667643
-
Newly recognized components of the renin-angiotensin system: Potential roles in cardiovascular and renal regulation
-
Carey RM, Siragy HM. Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. Endocr Rev. 2003;24(3):261-271.
-
(2003)
Endocr Rev
, vol.24
, Issue.3
, pp. 261-271
-
-
Carey, R.M.1
Siragy, H.M.2
-
7
-
-
0037154324
-
The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: Part I: oxidative stress and atherogenesis
-
Nickenig G, Harrison DG. The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: part I: oxidative stress and atherogenesis. Circulation. 2002;105(3):393-396.
-
(2002)
Circulation
, vol.105
, Issue.3
, pp. 393-396
-
-
Nickenig, G.1
Harrison, D.G.2
-
8
-
-
0037192344
-
The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: Part II: AT(1) receptor regulation
-
Nickenig G, Harrison DG. The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: Part II: AT(1) receptor regulation. Circulation. 2002;105(4):530-536.
-
(2002)
Circulation
, vol.105
, Issue.4
, pp. 530-536
-
-
Nickenig, G.1
Harrison, D.G.2
-
9
-
-
34547129852
-
Rationale for double renin-angiotensinaldosterone system blockade
-
Unger T, Stoppelhaar M. Rationale for double renin-angiotensinaldosterone system blockade. Am J Cardiol. 2007;100(3A):25J-31J.
-
(2007)
Am J Cardiol
, vol.100
, Issue.3 A
-
-
Unger, T.1
Stoppelhaar, M.2
-
10
-
-
0020448825
-
Antihypertensive therapy with MK 421: Angiotensin II - renin relationships to evaluate efficacy of converting enzyme blockade
-
Biollaz J, Brunner HR, Gavras I, Waeber B, Gavras H. Antihypertensive therapy with MK 421: angiotensin II - renin relationships to evaluate efficacy of converting enzyme blockade. J Cardiovasc Pharmacol. 1982;4(6):966-972.
-
(1982)
J Cardiovasc Pharmacol
, vol.4
, Issue.6
, pp. 966-972
-
-
Biollaz, J.1
Brunner, H.R.2
Gavras, I.3
Waeber, B.4
Gavras, H.5
-
11
-
-
0029550256
-
Aldosterone escape during ACE inhibitor therapy in chronic heart failure
-
Struthers AD. Aldosterone escape during ACE inhibitor therapy in chronic heart failure. Eur Heart J. 1995;16(Suppl N):103-106.
-
(1995)
Eur Heart J
, vol.16
, Issue.SUPPL.
, pp. 103-106
-
-
Struthers, A.D.1
-
12
-
-
0036839716
-
Angiotensin receptor blockers: How important is selectivity?
-
Siragy HM. Angiotensin receptor blockers: how important is selectivity? Am J Hypertens. 2002;15(11):1006-1014.
-
(2002)
Am J Hypertens
, vol.15
, Issue.11
, pp. 1006-1014
-
-
Siragy, H.M.1
-
13
-
-
0037079309
-
Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies
-
Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903-1913.
-
(2002)
Lancet
, vol.360
, Issue.9349
, pp. 1903-1913
-
-
Lewington, S.1
Clarke, R.2
Qizilbash, N.3
Peto, R.4
Collins, R.5
-
14
-
-
0242654867
-
Effects of different blood-pressure-lowering regimens on major cardiovascular events: Results of prospectively-designed overviews of randomised trials
-
Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362(9395):1527-1535.
-
(2003)
Lancet
, vol.362
, Issue.9395
, pp. 1527-1535
-
-
Turnbull, F.1
-
15
-
-
34250350040
-
Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)
-
Mancia G, De Backer G, Dominiczak A, et al. Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25(6):1105-1187.
-
(2007)
J Hypertens
, vol.25
, Issue.6
, pp. 1105-1187
-
-
Mancia, G.1
De Backer, G.2
Dominiczak, A.3
-
16
-
-
0037534905
-
The Study on Cognition and Prognosis in the Elderly (SCOPE): Principal results of a randomized double-blind intervention trial
-
Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21(5):875-886.
-
(2003)
J Hypertens
, vol.21
, Issue.5
, pp. 875-886
-
-
Lithell, H.1
Hansson, L.2
Skoog, I.3
-
17
-
-
0037160968
-
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol
-
Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):995-1003.
-
(2002)
Lancet
, vol.359
, Issue.9311
, pp. 995-1003
-
-
Dahlof, B.1
Devereux, R.B.2
Kjeldsen, S.E.3
-
18
-
-
2942635317
-
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial
-
Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363(9426):2022-2031.
-
(2004)
Lancet
, vol.363
, Issue.9426
, pp. 2022-2031
-
-
Julius, S.1
Kjeldsen, S.E.2
Weber, M.3
-
19
-
-
34247379373
-
Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): A randomised, open-label, blinded endpoint morbidity-mortality study
-
Mochizuki S, Dahlof B, Shimizu M, et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet. 2007;369(9571):1431-1439.
-
(2007)
Lancet
, vol.369
, Issue.9571
, pp. 1431-1439
-
-
Mochizuki, S.1
Dahlof, B.2
Shimizu, M.3
-
20
-
-
42049107348
-
Telmisartan, ramipril, or both in patients at high risk for vascular events
-
Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547-1459.
-
(2008)
N Engl J Med
, vol.358
, Issue.15
, pp. 1547-1459
-
-
Yusuf, S.1
Teo, K.K.2
Pogue, J.3
-
21
-
-
0031800774
-
Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators
-
Kassler-Taub K, Littlejohn T, Elliott W, Ruddy T, Adler E; Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators. Am J Hypertens. 1998;11(4 Pt 1):445-453.
-
(1998)
Am J Hypertens
, vol.11
, Issue.4 PART 1
, pp. 445-453
-
-
Kassler-Taub, K.1
Littlejohn, T.2
Elliott, W.3
Ruddy, T.4
Adler, E.5
-
22
-
-
0344289511
-
ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension
-
Mallion J, Siche J, Lacourciere Y. ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension. J Hum Hypertens. 1999;13(10):657-664.
-
(1999)
J Hum Hypertens
, vol.13
, Issue.10
, pp. 657-664
-
-
Mallion, J.1
Siche, J.2
Lacourciere, Y.3
-
23
-
-
0031882729
-
The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan
-
Andersson OK, Neldam S. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan. Blood Press. 1998;7(1):53-59.
-
(1998)
Blood Press
, vol.7
, Issue.1
, pp. 53-59
-
-
Andersson, O.K.1
Neldam, S.2
-
24
-
-
0032899960
-
A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension
-
Hedner T, Oparil S, Rasmussen K, et al. A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension. Am J Hypertens. 1999;12(4 Pt 1):414-417.
-
(1999)
Am J Hypertens
, vol.12
, Issue.4 PART 1
, pp. 414-417
-
-
Hedner, T.1
Oparil, S.2
Rasmussen, K.3
-
25
-
-
0010838455
-
Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: A systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group
-
Flather MD, Yusuf S, Kober L, et al; Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet. 2000;355(9215):1575-1581.
-
(2000)
Lancet
, vol.355
, Issue.9215
, pp. 1575-1581
-
-
Flather, M.D.1
Yusuf, S.2
Kober, L.3
-
26
-
-
0037036971
-
Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: The OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan
-
Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet. 2002;360(9335):752-760.
-
(2002)
Lancet
, vol.360
, Issue.9335
, pp. 752-760
-
-
Dickstein, K.1
Kjekshus, J.2
-
27
-
-
0242490542
-
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both
-
Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349(20):1893-1906.
-
(2003)
N Engl J Med
, vol.349
, Issue.20
, pp. 1893-1906
-
-
Pfeffer, M.A.1
McMurray, J.J.2
Velazquez, E.J.3
-
28
-
-
0030902115
-
Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)
-
Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet. 1997;349(9054):747-752.
-
(1997)
Lancet
, vol.349
, Issue.9054
, pp. 747-752
-
-
Pitt, B.1
Segal, R.2
Martinez, F.A.3
-
29
-
-
0034612118
-
Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial - the Losartan Heart Failure Survival Study ELITE II
-
Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355(9215):1582-1587.
-
(2000)
Lancet
, vol.355
, Issue.9215
, pp. 1582-1587
-
-
Pitt, B.1
Poole-Wilson, P.A.2
Segal, R.3
-
30
-
-
0035818884
-
A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure
-
Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345(23):1667-1675.
-
(2001)
N Engl J Med
, vol.345
, Issue.23
, pp. 1667-1675
-
-
Cohn, J.N.1
Tognoni, G.2
-
31
-
-
0041408235
-
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARM-Added trial
-
McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362(9386):767-771.
-
(2003)
Lancet
, vol.362
, Issue.9386
, pp. 767-771
-
-
McMurray, J.J.1
Ostergren, J.2
Swedberg, K.3
-
32
-
-
0041909380
-
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: The CHARM-Alternative trial
-
Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003;362(9386):772-776.
-
(2003)
Lancet
, vol.362
, Issue.9386
, pp. 772-776
-
-
Granger, C.B.1
McMurray, J.J.2
Yusuf, S.3
-
33
-
-
0041408234
-
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial
-
Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362(9386):777-781.
-
(2003)
Lancet
, vol.362
, Issue.9386
, pp. 777-781
-
-
Yusuf, S.1
Pfeffer, M.A.2
Swedberg, K.3
-
34
-
-
57349142933
-
Irbesartan in patients with heart failure and preserved ejection fraction
-
Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359(23):2456-2467.
-
(2008)
N Engl J Med
, vol.359
, Issue.23
, pp. 2456-2467
-
-
Massie, B.M.1
Carson, P.E.2
McMurray, J.J.3
-
35
-
-
0027517659
-
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group
-
Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329(20):1456-1462.
-
(1993)
N Engl J Med
, vol.329
, Issue.20
, pp. 1456-1462
-
-
Lewis, E.J.1
Hunsicker, L.G.2
Bain, R.P.3
Rohde, R.D.4
-
36
-
-
0027517013
-
Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients
-
Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med. 1993;118(8):577-581.
-
(1993)
Ann Intern Med
, vol.118
, Issue.8
, pp. 577-581
-
-
Ravid, M.1
Savin, H.2
Jutrin, I.3
Bental, T.4
Katz, B.5
Lishner, M.6
-
37
-
-
0035922444
-
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
-
Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345(12):870-878.
-
(2001)
N Engl J Med
, vol.345
, Issue.12
, pp. 870-878
-
-
Parving, H.H.1
Lehnert, H.2
Brochner-Mortensen, J.3
Gomis, R.4
Andersen, S.5
Arner, P.6
-
38
-
-
0035922441
-
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
-
Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861-869.
-
(2001)
N Engl J Med
, vol.345
, Issue.12
, pp. 861-869
-
-
Brenner, B.M.1
Cooper, M.E.2
de Zeeuw, D.3
-
39
-
-
0035922447
-
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
-
Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851-860.
-
(2001)
N Engl J Med
, vol.345
, Issue.12
, pp. 851-860
-
-
Lewis, E.J.1
Hunsicker, L.G.2
Clarke, W.R.3
|